However, in the AWARD 7 trial, a dedicated 52-week trial of dulaglutide in patients with diabetic kidney disease, stage 3-4, the decline with time was significantly reduced compared with insulin glargine [29]
The data document a molecular mechanism in the model, not a clinical benefit
The ongoing TRIUMPH program represents the critical next step in determining whether retatrutides promise will translate into regulatory approval and clinical practice
A dual agonist for GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR), discussed later, may attenuate these side effects through GIP receptor signaling
Oxidant-induced apoptosis in human retinal pigment epithelial cells: dependence on extracellular redox state
Retatrutide is a prescription medication used to support weight loss and metabolic health